Anti-PD-1/PD-L1 Antibodies Combine with Chemotherapy or CTLA4 Antibodies for First-Line Treatment of Advanced Lung Cancer

被引：0
|
作者：
Fan, Y. [1 ]
Xu, X. [2 ]
机构：
[1] Zhejiang Canc Hosp, Chemotherapy, Hangzhou, Zhejiang, Peoples R China
[2] Zhejiang Prov Canc Hosp, Hangzhou, Zhejiang, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
lung cancer; Checkpoint inhibitors; chemotherapy;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.07-057
引用
收藏
页码：S2149 / S2150
页数：2
相关论文
共 50 条
  • [1] The efficacy and safety of anti-PD-1/PD-L1 antibodies combined with chemotherapy or CTLA4 antibody as a first-line treatment for advanced lung cancer
    Xu, Xiaoling
    Huang, Zhiyu
    Zheng, Lei
    Fan, Yun
    INTERNATIONAL JOURNAL OF CANCER, 2018, 142 (11) : 2344 - 2354
  • [2] Combination of anti-PD-1/PD-L1 antibodies with chemotherapy or CTL4 antibodies for first-line treatment of advanced lung cancer.
    Fan, Yun
    Xu, Xiaoling
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [3] The efficacy and safety of anti-PD-1/PD-L1 antibodies combined with chemotherapy or CTLA4 antibody as a first-line treatment for advanced lung cancer (vol 142, pg 2344, 2018)
    Zhang, Bo
    Wu, Qiong
    INTERNATIONAL JOURNAL OF CANCER, 2019, 144 (07) : E2 - E2
  • [4] The efficacy and safety of anti-PD-1/PD-L1 antibodies combined with chemotherapy or CTLA4 antibody as a first-line treatment for advanced lung cancer (vol 142, pg 2344, 2018)
    Xu, X.
    Huang, Z.
    Zheng, L.
    Fan, Y.
    INTERNATIONAL JOURNAL OF CANCER, 2018, 143 (05) : E8 - E8
  • [5] Effectiveness and safety of PD-1/PD-L1 or CTLA4 inhibitors combined with chemotherapy as a first-line treatment for lung cancer: A meta-analysis
    Shen, Kaikai
    Cui, Jinggang
    Wei, Yuqing
    Chen, Xiaojun
    Liu, Guohua
    Gao, Xiaolai
    Li, Wei
    Lu, Huiling
    Zhan, Ping
    Lv, Tangfeng
    Lin, Dang
    JOURNAL OF THORACIC DISEASE, 2018, 10 (12) : 6636 - 6652
  • [6] Predictive Markers for the Efficacy of Anti-PD-1/PD-L1 Antibodies in Lung Cancer
    Shukuya, Takehito
    Carbone, David P.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (07) : 976 - 988
  • [7] Combination immunotherapy using anti-PD-1/PD-L1 plus anti-CTLA-4 antibodies
    Reck, Martin
    ANNALS OF ONCOLOGY, 2021, 32 : S249 - S249
  • [8] Anti-PD1 or anti-PD-L1 antibodies alone or in combination with chemotherapy first-line treatment of advanced non-small cell lung cancer
    Zhang Xuexia
    Cai Xiaoping
    Zheng Hao
    THORACIC CANCER, 2022, 13 (07) : 1104 - 1105
  • [9] Effectiveness and safety of anlotinib plus anti-programmed cell death 1/ligand 1 (anti-PD-1/PD-L1) antibodies as maintenance therapy after first-line chemotherapy combined with anti-PD-1/ PD-L1 antibodies in extensive-stage small cell lung cancer: a real world study
    Yang, Pan
    Luo, Hu
    Zhao, Lintao
    Xiong, Fu
    Tang, Chunlan
    JOURNAL OF THORACIC DISEASE, 2024, 16 (07) : 4391 - 4399
  • [10] The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients
    Sui, Xinbing
    Ma, Junhong
    Han, Weidong
    Wang, Xian
    Fang, Yong
    Li, Da
    Pan, Hongming
    Zhang, Li
    ONCOTARGET, 2015, 6 (23) : 19393 - 19404
12345